Evacetrapib

DB11655InvestigationalSmall molecule

Evacetrapib has been used in trials studying the basic science and treatment of Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Hepatic Insufficiency, and Cardiovascular Disease.

Mechanism: Pharmacologically active on Cholesteryl ester transfer protein
Curator reviewed
Formula / weight: C₃₁H₃₆F₆N₆O₂ · 638.659 g/mol (avg)
Code names: LY2484595

Resolves to

Compound

UNII51XWV9K850CAS1186486-62-3ChEMBLCHEMBL2017179PubChem49836058

Structure

InChIKeyIHIUGIVXARLYHP-YBXDKENTSA-NSMILESCN1N=NC(=N1)N(CC1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)[C@H]1CCCN(C[C@H]2CC[C@@H](CC2)C(O)=O)C2=C1C=C(C)C=C2C

Targets

P11597CETP

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Evacetrapib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account